PTX (ASX) Ann: PTX data demonstrates key OmniCAR features in next gen CAR-T

Originally posted by Agent-86: ↑

PTX's secret T-Cell projects with PeterMac have got me intrigued.
I refer to the following slide from their AGM slide pack:

I had a look around the research project area on the PeterMac website this afternoon and came across the following which seems like it may be related to the secret discussions going on in the background.

https://foundation.petermac.org/your-dollars-in-action/updates-researchers/immunotherapy-delivers-new-hope

Your dollars in action > Updates from researchers > New discoveries are closer to becoming cures

New discoveries are closer to becoming cures
Associate Professor Paul Neeson and his team have been exploring how, through immunotherapy, they can use a combination of drugs to stimulate the immune system and boost the body’s own defences against blood cancers, like multiple myeloma.
Associate Professor Paul Neeson is a Group Leader within Peter Mac’s Cancer Immunology Program.
He explains: “We now have drugs called antibodies, which target the cancer by co-opting the immune system cells... These antibodies have been very successful when used in combination with other drugs."
“There are some really exciting antibodies being developed. One of them is called a biospecific engager, which is where one arm of an antibody binds to a receptor on a white blood cell called a T-cell, activating it, and where another arm binds to a myeloma cell. This forms a bridge between the cells, and engages those T-cells to attack the myeloma.”
A/Prof Neeson is excited to be exploring a new discovery involving chimeric antigen receptor T-cells (CAR T) - immune cells that are used to target specific proteins.
Taking the next step
“We have changed human CAR T-cell production to now generate ‘early’ CAR T-cells, which shows exciting potential," he says.
“We believe these ‘early’ CAR T-cells can be readily translated to the clinic and will form a fundamental platform upon which new treatment strategies will be built.”
While immunotherapy holds many promises for new treatments, there are still some limits to its effectiveness for many patients. The cancer itself can suppress a patient’s immune system which limits the ability for CAR T-cells to attack tumour cells.
A/Prof Neeson is hopeful that these early CAR T-cells can help to overcome some of these challenges. He also hopes to further enhance how CAR T-cells respond to the different genetic make-up of tumours.
“Currently there are many patients with cancer who do not respond to immunotherapy. Our study of early CAR T-cells will provide alternate treatment strategies to improve their responses to immunotherapy.”
Should A/Prof Neeson’s theory prove correct, this discovery could improve the effectiveness of treatment for many cancer patients.

THANK YOU
Promising developments such as this one are essential in the search for more cancer cures – cures that will save more lives.
Thank you to all of our generous supporters who make this vital research possible.

Certainly sounds like a good fit for the OmniCAR platform.

Expand

Great find A86 and thanks for sharing. The possibilities are endless I feel for PTXs OmniCAR and the stealth cell tech program is indeed very intriguing!

More than ever, I'm confident there will be a handful of huge rerates next year!!

No.	Vol.	Price($)
11	881755	3.8¢

No.

Vol.

Price($)

881755

3.8¢

Price($)	Vol.	No.
3.9¢	150000	2

Price($)

Vol.

No.

3.9¢

150000

No.	Vol.	Price($)
8	802755	0.038
5	393000	0.037
8	688946	0.036
7	500304	0.035
2	140000	0.034

No.

Vol.

Price($)

802755

0.038

393000

0.037

688946

0.036

500304

0.035

140000

0.034

Price($)	Vol.	No.
0.039	150000	2
0.040	200000	2
0.041	66157	1
0.042	180000	2
0.043	200000	1

Price($)

Vol.

No.

0.039

150000

0.040

200000

0.041

66157

0.042

180000

0.043

200000

(20min delay)
Last 3.8¢		Change -0.001(2.56%)		Mkt cap ! $30.60M

Open	High	Low	Value	Volume
3.9¢	3.9¢	3.8¢	$47.91K	1.256M

Great find A86 and thanks for sharing. The possibilities are...

New discoveries are closer to becoming cures

Taking the next step

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Great find A86 and thanks for sharing. The possibilities are...

New discoveries are closer to becoming cures

Taking the next step

Top Stories

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News